-
RegMed XB is a translational product development platform that brings together Dutch and Flemish public and private stakeholders to accelerate the development of innovative regenerative therapies.
Infrastructure: RegMed XB's Pilot Factory
A seamless pathway for innovators to accelerate, de-risk, and scale regenerative therapies
read more
-
Maurice Horsten joins RegMed XB Supervisory Board
We are pleased to announce that, as of June 1, 2024, Maurice Horsten will be joining our Supervisory Board.
read more
Grand Opening of ICAT's New Lab Facility in Zeist
We are pleased to announce the successful official opening of the Innovation Center for Advanced Therapies (ICAT) in Zeist, located at the Utrecht Science Park, which took place on Thursday, May 23, 2024.
read more
€30 million subsidy for Regenerative Medicine Projects
Important news for small and medium-sized enterprises (SMEs) in the biomedical sector! A new government subsidy has been launched, providing €30 million to support innovation in regenerative medicine.
read more -
Moonshots (research excellence)
-
Pilot Factory (infrastructure)
The RegMed XB Pilot Factory is one of the largest international infrastructures for regenerative medicine. It brings together all the expertise and infrastructure needed to bring regenerative medicine to the market.
-
RegMed XB's Ecosystem
Health Foundations
The following Dutch health foundations are involved in defining research objectives and provide guidance in the research we conduct to ensure we maintain focus on the patient.
read moreAcademic Partners
RegMed XB works together with (inter)national top-rated academic institutions and collaborates specifically and exclusively with researchers who contribute specific expertise to the Moonshot initiatives.
read moreIndustrial Partners
Partnering with companies offers access to their expertise in designing scalable and feasible products. Currently, we have strong partnerships with the following entities.
read moreGovernmental Partners
RegMed XB receives support from national and local governments to de-risk promising concepts from academia to proof of concept or initial clinical trial stages.
read more -
-
-
-
-
-
-